盐酸安罗替尼治疗晚期非小细胞肺癌的临床效果及预后影响因素分析

Analysis of the clinical effect and prognostic factors in the treatment of advanced non-small cell lung cancer with anlotinib hydrochloride

目的探讨盐酸安罗替尼治疗晚期非小细胞肺癌(NSCLC)的临床效果及预后影响因素。方法选取2018年7月至2019年6月在本院治疗的非小细胞肺癌患者56例作为研究对象,均给予口服盐酸安罗替尼治疗。随访6个月,评价盐酸安罗替尼治疗NSCLC的临床疗效及安全性,并分析患者预后影响因素。结果随访时间内,56例患者中完全缓解0例、部分缓解16例、稳定18例、进展22例,疾病缓解率为28.6%(16/56),疾病控制率为60.7%(34/56)。患者出现的不良反应主要包括中性粒细胞减少、血小板减少、乏力、胃肠道反应、肝功能损伤、食欲下降、黏膜炎,大部分属于1~2级不良反应。单因素分析结果显示,性别、年龄、吸烟史、脑转移与患者预后无明显相关性,而鳞癌、Ⅲb期、安罗替尼三线治疗的NSCLC患者预后更佳(P<0.05)。结论盐酸安罗替尼治疗NSCLC具有较好的临床疗效和安全性,且NSCLC患者预后与病理类型、临床分期、安罗替尼治疗时机有关。

Objective To explore the clinical effect and prognostic factors of the treatment of advanced non-small cell lung cancer(NSCLC)with anlotinib hydrochloride.Methods 56 cases of NSCLC treated in our hospital from July 2018 to June 2019 were selected as the reseach subjects.All patients were treated with oral administration of anlotinib hydrochloride.After 6 months follow-up,the clinical efficacy and safety of anlotinib hydrochloride in the treatment of NSCLC were evaluated,and the prognostic factors were analyzed.Results During the follow-up period,among 56 patients,0 achieved complete remission,16 achieved partial remission,18 achieved stability and 22 achieved progress.The disease remission rate was 28.6%(16/56),and the disease control rate was 60.7%(34/56).The adverse reactions of patients mainly include neutropenia,thrombocytopenia,asthenia,gastrointestinal reaction,liver function damage,appetite decline,mucositis,most of which belong to 1-2 grade adverse reactions.The results of univariate analysis showed that gender,age,smoking history,brain metastasis were not significantly correlated with the prognosis.The prognosis of NSCLC patients with squamous cell carcinoma,stageⅢb and the third line treatment of anlotinib hydrochloride was better(P<0.05).Conclusion The clinical efficacy and safety of anlotinib hydrochloride in the treatment of NSCLC are better,and the prognosis of NSCLC patients is related to pathological type,clinical stage and the opportunity of treatment with anlotinib hydrochloride.